Alterity Therapeutics (ATHE) shares were sharply higher Thursday morning after the company said that its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.
The result was achieved at the 50 mg dose at week 52 when compared with placebo, Alterity said.
The company also said that ATH434 was well-tolerated, with no reported serious adverse events.
Price: 5.48, Change: +2.49, Percent Change: +83.28
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。